Related references
Note: Only part of the references are listed.National Kidney Foundation 2009 Spring Clinical Meetings Abstracts March 25–29, 2009
ADVANCES IN CHRONIC KIDNEY DISEASE (2009)
Chronic Pharmacological and Safety Evaluation of Hematide™, a PEGylated Peptidic Erythropoiesis-Stimulating Agent, in Rodents
Kathryn W. Woodburn et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
Chronic preclinical safety evaluation of Hematide (TM), a pegylated peptidic erythropoiesis stimulating agent in monkeys
Kathryn W. Woodburn et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers
Sukyung Woo et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Comparative erythropoietin receptor binding kinetics of CERA and epoetin-beta determined by surface plasmon resonance and competition binding assay
Michael Jarsch et al.
PHARMACOLOGY (2008)
Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model
Kathryn W. Woodburn et al.
EXPERIMENTAL HEMATOLOGY (2007)
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia
Qing Fan et al.
EXPERIMENTAL HEMATOLOGY (2006)
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers
Richard B. Stead et al.
BLOOD (2006)
Differentiating factors between erythropoiesis-stimulating agents - A guide to selection for anaemia of chronic kidney disease
R Deicher et al.
DRUGS (2004)
Share Paper
